Orphanet: Búsqueda por enfermedad/gen
x

Búsqueda de un proyecto

* (*) Campo obligatorio

139 Resultado(s)

Financiado por un miembro del IRDiRC =

Proyectos de investigación

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCExploration of basic pathogenesis of imprinting disorders
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCNext-generation treatment strategy of Parkinson's disease by Precision Medicine
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of Gene Therapy for Mucopolysaccharidosis Type II
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCPreclinical study of self-degradable against pathogenic TDP-43 in ALS
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of RAS-related ALPS-like disease (RALD) therapy
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCSearch for new therapeutic seeds of CARASIL targeting TGF-beta signal
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of vascular patch for radical cure of the tetralogy of Fallot
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCPathogenesis and novel therapeutic approarches in RASoapthies
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of anti-mineralization drug
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDrug Screening for Parkinson's disease using patient-specific iPSCs.
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCClinical trial of gene therapy for AADC deficiency
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCGene therapy against SCA1 based on the molecular pathomechanism
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDeveloping new drugs for Niemann-Pick disease type C
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCEvidence-generating clinical research for myotonic dystrophy
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCCreation of comprehensive clinical guidelines on kernicterus of preterm infants
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of novel disease-causing gene based therapies for cardiomyopathies
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDrug discovery targeted to alternative splicing variants in congenital long-QT syndrome
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCTherapeutic strategies for patients with immunoproteasomes dysfunctions
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCInitiative on Rare and Undiagnosed Diseases (IRUD)
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of novel therapeutic drugs for congenital nephrogenic diabetes insipidus
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of gene therapy for cardiac regeneration in dilated cardiomyopathy
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCResearch for the development of precision medicine for autoimmune diseases
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment ofa new molecular targeted therapy for Fukuyama muscular dystrophy
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of a novel therapy for achondroplasia with anti-FGF2 aptamer
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCResearch for practical application of an innovative peptide drug for DMD
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of Novel ALK2 Inhibitor for FOP
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of anti-fibrotic drug for primary biliary cholangitis
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCThe investigation on the efficacy of new low molecular compound for systemic sclerosis
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of novel therapeutics for Fibrodysplasia Ossficancs Progressiva
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCMolecular basis research for exploring inovative therapies of Rett syndrome
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCElucidation of molecular pathogenesis of SLC29A3 disorders
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCA strategy to optimize treatment options for epidermolysis bullosa
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCStrategic research for the improvement of the ocular sequelae in SJS/TEN
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCStudy of clinical features and treatment of imprinting disorders and related disorders
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCNatural history of multiple system atrophy and the development of novel biomarkers
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCEstablishment of appropriate treatment for spinal and bulbar muscular atrophy
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCAdvancing Care of Rare/Intractable Adrenal Diseases in Japan Study
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCThe establishment of novel diagnostic methods for adult nephrotic syndrome.
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDevelopment of diagnostic system for Parkinson's disease using faty acid metabolites
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDesigning and development of a widely exploitable registry of rare intractable diseases
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDiscovery of novel therapeutic approach for Nakajo-Nishimura syndrome and Blau syndrome
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCDrug discovery for spinal-bulbar muscular atrophy using disease specific iPSCs
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCTreatment selection for the acute phase of Kawasaki disease using biomarkers
AMED - Japan Agency for Medical Research and Development

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

JAPON

JAPAN
TOKYO

Financiado por un miembro del IRDiRCEstablishment of Integrated Genome Analysis Center for Hereditary Muscle Disease
AMED - Japan Agency for Medical Research and Development